These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28367260)

  • 61. A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.
    Wilson AJ; Chang B; Taglienti AJ; Chin BC; Chang CS; Folsom N; Percec I
    Plast Reconstr Surg; 2016 May; 137(5):1424-1433. PubMed ID: 27119918
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of microneedle fractional radiofrequency therapy with intradermal botulinum toxin a injection for periorbital rejuvenation.
    Jeon IK; Chang SE; Park GH; Roh MR
    Dermatology; 2013; 227(4):367-72. PubMed ID: 24280617
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of AbobotulinumtoxinA Injections for Oily Skin of the Forehead: A Dose-Response Analysis.
    Kesty K; Goldberg DJ
    Dermatol Surg; 2021 Jan; 47(1):56-60. PubMed ID: 32769519
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature.
    Nofal E; Salem S; Khashaba SA
    Dermatol Surg; 2022 Aug; 48(8):843-848. PubMed ID: 35917265
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids.
    Carruthers A; Carruthers J
    Dermatol Surg; 2005 Oct; 31(10):1297-303. PubMed ID: 16188182
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The efficacy of intradermal injection of type A botulinum toxin for facial rejuvenation.
    Zhu J; Ji X; Xu Y; Liu J; Miao YY; Zhang JA; Luo D; Zhou BR
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27862727
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Botulinum toxin treatment of spasticity targeted to muscle endplates: an international, randomised, evaluator-blinded study comparing two different botulinum toxin injection strategies for the treatment of upper limb spasticity.
    Rekand T; Biering-Sörensen B; He J; Vilholm OJ; Christensen PB; Ulfarsson T; Belusa R; Ström T; Myrenfors P; Maisonobe P; Dalager T
    BMJ Open; 2019 May; 9(5):e024340. PubMed ID: 31061021
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
    Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Glabellar Lines: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials.
    Guo Y; Lu Y; Liu T; Zhou Y; Yang P; Zhu J; Chen L; Yang Q
    Plast Reconstr Surg; 2015 Sep; 136(3):310e-318e. PubMed ID: 26313835
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and Safety of Single Botulinum Toxin Type A (Botox®) Injection for Relief of Upper Trapezius Myofascial Trigger Point: A Randomized, Double-Blind, Placebo-Controlled Study.
    Kwanchuay P; Petchnumsin T; Yiemsiri P; Pasuk N; Srikanok W; Hathaiareerug C
    J Med Assoc Thai; 2015 Dec; 98(12):1231-6. PubMed ID: 27004309
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
    Shome D; Kapoor R; Khare S
    J Cosmet Dermatol; 2019 Dec; 18(6):1635-1641. PubMed ID: 31135088
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Subjective and Objective Measurements of the Facial Effects of Microdoses of Botulinum Toxin.
    Hexsel D; Valente-Bezerra I; Mosena G; Oakim Mourao MA; Fabris VC
    Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557136
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines.
    Dayan S; Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Munavalli G; Prygova I
    J Cosmet Dermatol; 2022 Jun; 21(6):2407-2416. PubMed ID: 35266281
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Digital Image Speckle Correlation to Optimize Botulinum Toxin Type A Injection: A Prospective, Randomized, Crossover Trial.
    Verma R; Klein G; Xu Y; Rafailovich M; Gilbert Fernandez JJ; Khan SU; Bui DT; Dagum AB
    Plast Reconstr Surg; 2019 Jun; 143(6):1614-1618. PubMed ID: 31136474
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
    Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
    Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.
    Patel AT; Lew MF; Dashtipour K; Isaacson S; Hauser RA; Ondo W; Maisonobe P; Wietek S; Rubin B; Brashear A
    PLoS One; 2021; 16(2):e0245827. PubMed ID: 33524060
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Facial rejuvenation after intradermal botulinum toxin: is it really the botulinum toxin or is it the pricks?
    Kapoor R; Shome D; Jain V; Dikshit R
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2098-105. PubMed ID: 21134041
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of the safety and efficacy of a biosimilar abobotulinum toxin type A in treating moderate-to-severe glabellar lines: A non-inferiority double blinded randomized controlled trial.
    Afshani SM; Samadi A; Ayatollahi A; Kashani MN; Ahmad Nasdrollahi S; Hosseini H; Rezagholi Z; Hedayatjoo B; Hazegh Fetratjoo D; Ghobadi MA; Anari A; Saeedifar S; Firooz A
    J Cosmet Dermatol; 2022 Jun; 21(6):2398-2406. PubMed ID: 35340107
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction.
    De Boulle K; Fagien S; Sommer B; Glogau R
    Clin Interv Aging; 2010 Apr; 5():101-18. PubMed ID: 20458348
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.
    Magid M; Reichenberg JS; Poth PE; Robertson HT; LaViolette AK; Kruger TH; Wollmer MA
    J Clin Psychiatry; 2014 Aug; 75(8):837-44. PubMed ID: 24910934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.